VMAC (INTRAVENOUS NESERITIDE) 2002

NCT00083772

A randomised clinical trial investigating the effect of nesiritide versus placebo in acutely decompensated heart failure requiring hospitalization

1 Treatments

<table>
<thead>
<tr>
<th>Studied treatment</th>
<th>intravenous nesiritide for 3 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control treatment</td>
<td>placebo</td>
</tr>
</tbody>
</table>

2 Patients

<table>
<thead>
<tr>
<th>Patients</th>
<th>acutely decompensated heart failure requiring hospitalization</th>
</tr>
</thead>
</table>

2 Patients

3 Methods

<table>
<thead>
<tr>
<th>Blinding</th>
<th>double-blind</th>
</tr>
</thead>
<tbody>
<tr>
<td>Design</td>
<td>-</td>
</tr>
<tr>
<td>Centers</td>
<td>55</td>
</tr>
<tr>
<td>Geographical area</td>
<td>USA</td>
</tr>
<tr>
<td>Sample size</td>
<td>346 (204/142)</td>
</tr>
<tr>
<td>ArretTrt1</td>
<td>-</td>
</tr>
<tr>
<td>ArretTrt0</td>
<td>-</td>
</tr>
<tr>
<td>PeriodeInclusion</td>
<td>-</td>
</tr>
<tr>
<td>Hypothese</td>
<td>-</td>
</tr>
</tbody>
</table>
## 4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>amelioration of Dyspnea at 24 h</td>
<td>-/204</td>
<td>-/142</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>30 day death</td>
<td>-/204</td>
<td>-/142</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>30-d HF rehospitalization</td>
<td>-/204</td>
<td>-/142</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>30-d death or HF hospitalization</td>
<td>-/204</td>
<td>-/142</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Amelioration of Dyspnea at 6 h</td>
<td>-/204</td>
<td>-/142</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all cause death</td>
<td>-/204</td>
<td>-/142</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

## 5 References

JAMA 2002 Mar 27;287:1531-40 [11911755]

## 6 Comments